I wonder if Nipent EU sale could be in jeopardy. The latest news has Mayne Pharma being acquired by an competitor. This could be good news or bad news. They may not have the same outlook for Nipent or they may have deeper pockets to purchase rights in EU? It may also speed up the rights being purchased...new buyer may want deal already completed. Just do not want Nipent to get lost in the shuffle. Maybe we hear update at latest conference.